• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

Study of SPR Therapeutics’ Peripheral Nerve Stimulation System Demonstrates Significant and Sustained Relief of Post-Amputation Pain

April 8, 2019

SPRINT® 60-day PNS therapy demonstrates 12-month pain relief and 70 percent reduction in opioid use among those taking moderate to high doses

Cleveland, Ohio – April 8, 2019 — SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced the results of a study of its SPRINT® Peripheral Nerve Stimulation (PNS) System in the treatment of post-amputation pain.

SPR Therapeutics, Inc. SPRINT Peripheral Nerve Stimulation (PNS) System MicroLead
The SPR Therapeutics’ SPRINT Peripheral Nerve Stimulation (PNS) System MicroLead™ is constructed using a tiny 100-micron wire, about the size of a human hair. The leads are placed by a physician during an outpatient procedure without surgery, incisions, tissue destruction or anesthesia, and are connected to a wearable stimulator that delivers stimulation for up to 60 days of therapy, after which the leads are withdrawn. SPRINT has demonstrated significant and sustained pain relief across multiple studies. For additional information regarding safety and efficacy visit sprtherapeutic.wpengine.com.

The study demonstrated that short-term PNS therapy may provide enduring clinically significant pain relief, reduce opioid use and improve quality of life in patients with post-amputation pain, a type of neuropathic pain. This is the first study of an FDA-cleared PNS system to demonstrate statistically significant and clinically meaningful improvements in pain relief for both residual limb pain and phantom limb pain. The study, “Percutaneous Peripheral Nerve Stimulation for the Treatment of Chronic Neuropathic Post-Amputation Pain: A Multi-Center Randomized Placebo-Controlled Trial” has been published in Regional Anesthesia and Pain Medicine, the official peer-reviewed publication of the American Society of Regional Anesthesia and Pain Medicine (ASRA).

Study participants had experienced post-amputation pain for periods ranging from four months to more than 30 years. All participants underwent the minimally-invasive ultrasound-guided placement of SPR’s MicroLeads™ which are constructed using a tiny 100-micron wire, about the size of a human hair. Participants were randomized to receive SPRINT PNS therapy or placebo for four weeks. The placebo group then crossed over and all study participants received PNS for four subsequent weeks. A study participant was considered a success if they reported significant pain relief of at least 50 percent during the first four weeks.

The study demonstrated that a significantly greater proportion of the participants who received SPRINT PNS experienced significant pain relief (58 percent) compared to 14 percent of those who received placebo. The delivery of therapy for four additional weeks in the SPRINT PNS group resulted in 67 percent of the participants reporting significant pain relief. While prospective follow up is ongoing, of those participants who completed follow-up at 12 months, 80 percent reported continued relief with an average pain reduction of 76 percent. Furthermore, opioid use among moderate to high users (which represented about a quarter of the participants) decreased by more than 70 percent in the SPRINT PNS group compared to less than one percent in the placebo group. The most common side effect was skin irritation or redness at the lead exit site or related to the use of adhesive patches or bandages.  There were no serious side-effects.

Dr. Christopher Gilmore of the Center for Clinical Research in Winston-Salem, NC and principal author, stated: “Post-amputation pain has traditionally been one of the most challenging neuropathic conditions we treat as interventional pain management specialists. The data clearly demonstrate that the SPRINT PNS System is a safe and effective treatment option for post-amputation pain, with the potential to produce pain relief that endures well beyond the 60-day therapy period, after which the leads are withdrawn. Given the durability of pain relief we’re observing with SPRINT, many patients will appreciate that a permanently implanted system may be avoided. The non-opioid and minimally-invasive nature of SPRINT also bodes well for its use early in the care continuum for other painful neuropathic conditions.”

Neuropathic pain often occurs following an injury to peripheral nerves and is a common and challenging condition following amputation. There are approximately two million amputees in the United States, with nearly 200,000 amputations performed annually. The prevalence of persistent pain in this population has been reported to be as high as 74 percent for residual limb pain and 85 percent for phantom limb pain, with many patients experiencing pain of both types. This pain often impedes function, lowers quality of life, and leads to an increased risk of depression.

According to Paul Bernacchio, President of the National Amputation Foundation, “The study results reported by the SPR Therapeutics team are great news to the amputee and Veteran communities we represent. We are in desperate need of more effective, less invasive early interventions to address the significant issue of post-amputation pain. The enduring effects of this short-term therapy and its minimally-invasive nature make it a very compelling therapy for those suffering post-amputation pain.”

“SPR Therapeutics is very appreciative of the support of our physician investigators and sincerely grateful to our study volunteers,” said Maria Bennett, CEO of SPR Therapeutics, Inc.  “This latest study validates the durable results being achieved with our SPRINT PNS system. We continue to work with pain specialists on future studies as we further advance the growing body of evidence for SPRINT.”

About SPRINT® PNS System
The SPRINT Peripheral Nerve Stimulation (PNS) System is the only percutaneous PNS device that is FDA-cleared for both chronic and acute pain, including post-operative and post-traumatic pain. The SPRINT PNS System leads are placed by a physician during an outpatient procedure without surgery, incisions, tissue destruction or anesthesia, and are connected to a wearable stimulator that delivers stimulation for up to 60 days of therapy, after which the leads are withdrawn. In multiple studies, the SPRINT system has demonstrated significant and sustained pain relief following the 60-day treatment. Physicians have used the SPRINT system to treat post-amputation pain, inoperable joint pain, lower back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement and surgical reconstruction (partial listing). For additional information regarding safety and efficacy visit sprtherapeutic.wpengine.com.

About SPR Therapeutics, Inc.
SPR Therapeutics, Inc. is a privately-held medical device company headquartered in Cleveland, Ohio, focused on developing, manufacturing and commercializing non-opioid, minimally invasive, treatment options that improve quality of life. The company’s SPRINT technology is the only percutaneous Peripheral Nerve Stimulation (PNS) System FDA-cleared to treat both chronic and acute pain. More information can be found at: sprtherapeutic.wpengine.com.

About this study
This multi-center, randomized, double-blinded, placebo-controlled, partial-crossover study enrolled 28 lower extremity amputees with post-amputation pain at six U.S. clinical sites. The study was funded by a grant from the United States Department of Defense, Congressionally Directed Medical Research Programs, Peer Reviewed Orthopaedic Research Program, under award: W81XWH-12-2-0132.

SPR Contact:
Mark Stultz
Senior Vice President
mstultz@sprtherapeutics.com
612-770-0390

Media Contact:
Helen Shik
Shik Communications LLC
ShikPR@sprtherapeutics.com
617-510-4373

GlobeNewswire Press Release
View this press release on GlobeNewswire’s site.

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: News
Previous Post:SPR Therapeutics Masters Peripheral Nerve Stimulation Therapies for Pain
Next Post:Peripheral Nerve Stimulation System May Provide Significant Pain Relief

Sidebar

Archives

Recent News

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo